Emergence of Infective Endocarditis Due to Serratia spp.: Results of a Multicenter Cohort.
| Title: | Emergence of Infective Endocarditis Due to Serratia spp.: Results of a Multicenter Cohort. |
|---|---|
| Authors: | McCrary LM; Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri USA.; Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina USA.; Slain D; Department of Clinical Pharmacy, West Virginia University, Morgantown, West Virginia, USA.; Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.; Shah S; Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.; Stoner BJ; Department of Pharmacy, University of Kentucky Medical Center, Lexington, Kentucky USA.; Marx AH; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA.; Schranz AJ; Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina USA. |
| Source: | Open forum infectious diseases [Open Forum Infect Dis] 2025 Jan 22; Vol. 12 (3), pp. ofaf036. Date of Electronic Publication: 2025 Jan 22 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Cary, NC : Published by Oxford University Press on behalf of the Infectious Diseases Society of America, [2014]- |
| Abstract: | Background: Infective endocarditis due to Serratia spp. (S-IE) has historically been considered a rare entity. Typically linked to injection drug use (IDU), S-IE appears to be a growing problem as the harms of unsafe drug use proliferate. However, guidance on therapy for Gram-negative IE remains limited.; Methods: This was a retrospective analysis of adults treated for S-IE at 4 academic health systems in different US states from 2015 to 2021. Multivariable logistic regression analyzed the association of inpatient mortality with procedural management and combination antibiotic treatment.; Results: A total of 159 cases of S-IE were identified with a qualitative overall increase across the period, and a peak in 2019, although trends varied by site. Seventy-five were due to IDU, 57% involved a single left-sided valve, and inpatient mortality was 21%. In adjusted analyses, including 117 cases from 3 sites, lower inpatient mortality was associated with procedural intervention (odds ratio 0.14; 95% confidence interval, .03-.64) and combination antibiotic therapy (odds ratio 0.15; 95% confidence interval, .03-.74).; Discussion: In this multicenter study, we found that S-IE may be increasing, is commonly associated with IDU, is treated with varying strategies and carries high inpatient mortality. Procedural intervention and combination antibiotics were associated with lower mortality. Our study is limited by varying methods of case identification and a lack of data on clinical severity and surgical indications. Further study is urgently needed to define best management practices.; (© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.) |
| Competing Interests: | Potential conflicts of interest. A.J.S., D.S., L.M.M., A.H.M., S.S., and B.J.S. report no conflicts. |
| References: | Ann Intern Med. 1976 Jan;84(1):29-35. (PMID: 1106290); Clin Infect Dis. 2023 Aug 22;77(4):518-526. (PMID: 37138445); Open Forum Infect Dis. 2023 Dec 11;11(1):ofad628. (PMID: 38179104); J Chemother. 2022 Oct;34(6):347-359. (PMID: 35209804); Int J Antimicrob Agents. 2023 Oct;62(4):106934. (PMID: 37500021); Front Antibiot. 2022 Jun 29;1:942721. (PMID: 39816409); Prev Med. 2022 Nov;164:107289. (PMID: 36209817); PLoS One. 2020 Mar 10;15(3):e0230199. (PMID: 32155223); Ther Adv Infect Dis. 2022 Feb 21;9:20499361221078116. (PMID: 35222998); Cureus. 2022 Jun 1;14(6):e25572. (PMID: 35784988); Circulation. 2015 Oct 13;132(15):1435-86. (PMID: 26373316); Eur Heart J. 2015 Nov 21;36(44):3075-3128. (PMID: 26320109); Open Forum Infect Dis. 2023 Feb 02;10(3):ofad052. (PMID: 36968963); J Antimicrob Chemother. 2023 Oct 3;78(10):2457-2461. (PMID: 37563876); Antimicrob Agents Chemother. 2001 Apr;45(4):999-1007. (PMID: 11257008); J Am Coll Cardiol. 2019 Feb 12;73(5):559-570. (PMID: 30732709); Eur J Intern Med. 2021 Oct;92:71-78. (PMID: 33980395); Am J Case Rep. 2023 Jul 06;24:e939292. (PMID: 37408296); Ann Intern Med. 2007 Dec 18;147(12):829-35. (PMID: 18087053); Cureus. 2021 Aug 21;13(8):e17346. (PMID: 34567887); Open Forum Infect Dis. 2017 Jun 21;4(3):ofx132. (PMID: 28852678); Arch Intern Med. 1980 Feb;140(2):199-202. (PMID: 6986128) |
| Grant Information: | K23 DA049946 United States DA NIDA NIH HHS |
| Contributed Indexing: | Keywords: bacteremia; endocarditis; gram negative; injection drug use; serratia |
| Entry Date(s): | Date Created: 20250306 Latest Revision: 20250308 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11879387 |
| DOI: | 10.1093/ofid/ofaf036 |
| PMID: | 40046889 |
| Database: | MEDLINE |
Journal Article